List of Excipients in Branded Drug OMLONTI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Santen Incorporated	OMLONTI	omidenepag isopropyl	65086-002	BENZALKONIUM CHLORIDE	2035-06-10
Santen Incorporated	OMLONTI	omidenepag isopropyl	65086-002	CITRIC ACID MONOHYDRATE	2035-06-10
Santen Incorporated	OMLONTI	omidenepag isopropyl	65086-002	EDETATE DISODIUM	2035-06-10
Santen Incorporated	OMLONTI	omidenepag isopropyl	65086-002	GLYCERIN	2035-06-10
Santen Incorporated	OMLONTI	omidenepag isopropyl	65086-002	HYDROCHLORIC ACID	2035-06-10

Omlonti Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Omlonti, the U.S. brand for omidenepag isopropyl ophthalmic solution 0.002%, uses a conventional preserved aqueous formulation built around a low-dose EP2 receptor agonist. Its commercial opportunity is tied to glaucoma and ocular-hypertension patients who need intraocular-pressure reduction but experience tolerability or adherence problems with prostaglandin analogs. The main excipient opportunities are preservative-free delivery, improved multidose packaging, lower-surface-dose formulations, and differentiated combination products.

Omlonti was approved by the FDA in September 2022 and is commercialized in the United States by Bausch + Lomb under a collaboration with Santen. The product is indicated for reduction of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.[1,2]

What is Omlonti and how does its formulation work?

Omlonti contains omidenepag isopropyl, a prodrug converted in the eye to omidenepag, a selective prostaglandin EP2 receptor agonist. It is dosed once daily as one drop in the affected eye.[1]

Omlonti composition and excipient functions

The FDA-approved product is a sterile, preserved ophthalmic solution containing 0.002% omidenepag isopropyl. The labeled inactive ingredients include:

Excipient or component	Likely formulation role
Glycerin	Tonicity adjustment and humectant function
Sodium phosphate monobasic monohydrate	Buffer component
Sodium phosphate dibasic anhydrous	Buffer component
Polysorbate 80	Solubilization and interfacial-stability support
Disodium edetate	Chelating agent that can improve preservative and formulation stability
Benzalkonium chloride	Multidose antimicrobial preservative
Hydrochloric acid and sodium hydroxide	pH adjustment
Purified water	Vehicle

The formulation is designed to keep a highly potent, low-dose active ingredient in a clear aqueous ophthalmic vehicle. The inclusion of polysorbate 80 indicates that interfacial adsorption, solubility, or physical stability was a relevant development consideration. Disodium edetate can bind trace metals that catalyze degradation and can improve preservative performance.

The product is supplied as a multidose ophthalmic solution. Benzalkonium chloride, commonly called BAK, supports repeated-use sterility but is also associated with ocular-surface tolerability concerns, particularly during chronic therapy.[1,3]

What excipients are protected by Omlonti-related intellectual property?

The commercial formulation is likely protected through a combination of active-ingredient patents, formulation claims, manufacturing processes, and regulatory exclusivity. The excipients themselves are generally not proprietary in isolation. The relevant protection is more likely to cover a specific combination of omidenepag isopropyl with concentration, pH, buffering system, surfactant, preservative, packaging, or stability limits.

Active-ingredient and formulation patent strategy

A potential Omlonti patent estate can include:

1. Composition-of-matter patents for omidenepag or related EP2 agonist compounds.
2. Prodrug patents covering omidenepag isopropyl.
3. Ophthalmic-use patents for glaucoma and ocular hypertension.
4. Formulation patents covering aqueous solutions and concentration ranges.
5. Stability patents covering pH, surfactant, chelator, buffer, or preservative combinations.
6. Manufacturing patents covering synthesis, purification, crystallization, or impurity control.
7. Device or container-closure patents covering multidose ophthalmic packaging.

The Orange Book is the controlling FDA database for patents and exclusivity associated with approved drug products. A current Omlonti freedom-to-operate assessment should distinguish listed patents from broader Santen or Bausch patent families that may not be listed against the approved product.[4]

What is the Omlonti exclusivity timeline?

Event	Date or status
Omidenepag approved in Japan as Eybelis	2018
U.S. FDA approval of Omlonti	September 2022
U.S. new chemical entity exclusivity	Expected to block ANDA approval for five years from approval, subject to FDA regulatory treatment
Earliest routine ANDA filing window	Generally four years after approval for a drug with five-year NCE exclusivity
Earliest standard ANDA approval window	Generally five years after approval, absent patent or exclusivity extensions
Pediatric exclusivity	Not established from the core FDA approval information
Patent expiration	Must be determined from current Orange Book listings and applicable patent-term adjustment or extension data

The five-year NCE framework is commercially important. It limits conventional generic approval activity during the initial exclusivity period, although competing products may enter through alternative regulatory routes or use different active ingredients. Listed patents can extend practical protection beyond regulatory exclusivity.[4,5]

What is the FDA and Orange Book status of Omlonti?

Omlonti has FDA approval for elevated intraocular pressure associated with ocular hypertension or open-angle glaucoma. The approved dosage is one drop once daily in the affected eye.[1]

The FDA label identifies the active ingredient, strength, inactive ingredients, storage conditions, administration instructions, and safety information. The Orange Book determines whether Omlonti has listed patents that must be addressed by an ANDA applicant through Paragraph IV certification or another statutory certification.[4]

What Paragraph IV challenges could affect Omlonti?

A generic applicant could file an ANDA with a Paragraph IV certification alleging that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. If the patent holder files suit within 45 days of receiving notice, FDA approval can be subject to a 30-month stay, subject to statutory exceptions and court outcomes.[5]

The most credible generic challenge targets would be:

• The active ingredient or prodrug patent, if still in force.
• A narrow ophthalmic formulation patent.
• A stability or concentration patent.
• A use patent covering glaucoma or ocular hypertension.
• A container or multidose delivery patent, if listed.

A generic applicant may avoid some formulation claims by using different buffers, surfactants, chelators, preservatives, or packaging. That strategy becomes more difficult if the listed claims are broad or if the approved product has limited formulation space because of solubility and stability constraints.

No public Omlonti litigation or settlement position should be inferred without a current court-docket and FDA Orange Book review. A Paragraph IV notice, patent suit, or authorized-generic agreement would materially change launch timing and value.

How strong is the Omlonti patent estate?

The estate appears strategically stronger around the active molecule and clinical use than around conventional excipients. Glycerin, phosphate buffers, polysorbate 80, disodium edetate, and benzalkonium chloride are widely used pharmaceutical ingredients. A patent claim directed only to those excipients would be vulnerable to design-around arguments unless it includes unusual concentration, pH, stability, or performance limitations.

Patent-strength assessment

Protection category	Expected commercial strength
Omidenepag or omidenepag-isopropyl composition	Potentially high, depending on remaining term and claim scope
Glaucoma or ocular-hypertension use	Moderate to high if claims cover approved dosing and patient population
Conventional preserved solution	Moderate if formulation parameters are narrow; lower if readily substituted
Polysorbate or phosphate system alone	Low to moderate because of broad prior use
Stability and impurity-control claims	Moderate to high if linked to manufacturing constraints
Multidose packaging	Moderate, with design-around risk
Preservative-free reformulation	Potentially valuable as a separate product strategy

The commercial value of formulation patents depends on whether a competitor can reproduce the clinical performance with a different excipient system. For ophthalmic products, equivalence may involve more than active concentration. Droplet size, pH, osmolality, viscosity, preservative exposure, container performance, and ocular-surface tolerability can influence product differentiation.

What formulation patents and reformulation opportunities exist?

The most attractive product-development opportunity is a preservative-free Omlonti formulation.

Preservative-free Omlonti

Chronic BAK exposure can contribute to ocular-surface irritation, tear-film disruption, and epithelial effects in some patients. A preservative-free version could target:

• Patients with dry eye or ocular-surface disease.
• Patients receiving multiple chronic glaucoma medications.
• Patients undergoing long-term therapy.
• Postoperative or elderly patients with lower tolerability.
• Prescribers seeking to reduce preservative burden.

A preservative-free presentation could use single-dose ampoules, unit-dose blow-fill-seal containers, or a preservative-free multidose valve system. Each option creates different manufacturing, filling, sterility, usability, and cost requirements.

The main technical issue is whether removing BAK changes chemical stability, microbial robustness, adsorption to packaging, or delivered dose. Disodium edetate and alternative packaging may support preservation strategy, but the product cannot rely on chelation alone as a substitute for an antimicrobial preservative in a conventional multidose bottle.

Alternative multidose systems

A preservative-free multidose bottle could offer the strongest commercial balance between patient convenience and ocular-surface differentiation. Potential systems include:

• One-way valve bottles.
• Airless pump containers.
• Metered-dose ophthalmic dispensers.
• Tip-sealed systems that reduce microbial ingress.
• Low-residual-volume packaging.

The device may support separate patent protection and create a manufacturing barrier. However, device development adds human-factors, extractables and leachables, container-closure integrity, dose uniformity, and regulatory-combination-product requirements.

Excipient substitution

Potential reformulation paths include:

Development goal	Potential approach	Main technical risk
Remove BAK	Preservative-free unit dose or sterile multidose device	Microbial control and packaging cost
Reduce irritation	Alternative preservative or lower preservative load	Preservative efficacy and chronic-use tolerance
Improve solubility	Surfactant substitution or concentration adjustment	Precipitation, degradation, and ocular irritation
Improve comfort	Osmolality and pH optimization	Stability and active absorption
Improve shelf life	Buffer, chelator, oxygen-control, or packaging changes	New stability profile
Reduce waste	Smaller bottle or metered-dose system	Dose delivery and adherence
Support combination therapy	Co-formulation with another glaucoma agent	Chemical compatibility and regulatory complexity

How does Omlonti compare with competing glaucoma drugs?

Omlonti competes primarily with prostaglandin analogs and other topical intraocular-pressure-lowering products.

Product class	Representative products	Key commercial characteristic
EP2 receptor agonist	Omlonti	Mechanistically differentiated from conventional prostaglandin analogs
Prostaglandin F2α analog	Latanoprost, travoprost, bimatoprost	Established first-line use and broad generic competition
Preservative-free prostaglandin	Tafluprost products and preservative-free versions of other agents	Strong ocular-surface positioning
Rho kinase inhibitor	Netarsudil, ripasudil in certain markets	Alternative mechanism; tolerability can limit use
Beta blocker	Timolol	Low-cost generic option; systemic contraindications
Carbonic anhydrase inhibitor	Dorzolamide, brinzolamide	Often used alone or in combinations
Alpha agonist	Brimonidine	Generic availability and tolerability limitations

Omlonti’s differentiation is based on EP2 agonism, once-daily dosing, and a mechanism that does not replicate the standard prostaglandin F2α pathway. Its commercial challenge is payer and prescriber substitution by low-cost generic latanoprost and established branded or generic combinations.

A preservative-free version would improve Omlonti’s competitive position against preservative-free prostaglandin products. It would not eliminate the price disadvantage against generic products, but it could support formulary segmentation and specialist prescribing.

What licensing deals affect Omlonti?

Santen developed omidenepag and commercializes the product in markets outside the territories assigned to partners. Bausch + Lomb and Santen entered a collaboration covering development and commercialization of omidenepag ophthalmic solution in the United States and Canada.[2,6]

The arrangement gives Bausch + Lomb commercial access to a differentiated glaucoma product and gives Santen access to Bausch’s North American ophthalmology infrastructure. Licensing economics, milestone payments, royalties, and territory-specific rights should be reviewed in the parties’ public filings and transaction disclosures. No separate excipient-focused licensing transaction is established by the core product information.

A future preservative-free or device-enabled Omlonti product could be licensed separately from the base product, particularly if the innovation depends on proprietary packaging technology rather than a new active formulation.

What generic-entry risks exist for Omlonti?

Omlonti faces four principal entry risks:

1. An ANDA applicant challenges listed patents through Paragraph IV certification.
2. A generic manufacturer develops a bioequivalent ophthalmic solution using a different excipient system.
3. A competing glaucoma product captures patients through lower price or formulary preference.
4. An alternative EP2 or prostaglandin product reaches the market with preservative-free positioning.

Ophthalmic generics can design around excipient claims more easily when the active ingredient is stable across several pH, buffer, and surfactant systems. Generic substitution becomes more difficult when the reference product depends on a narrow solubility window, specialized packaging, or a difficult impurity profile.

Authorized-generic entry is another commercial variable. A brand-linked generic could preserve some channel access while reducing third-party generic economics. No public Omlonti authorized-generic arrangement is established in the cited FDA and company materials.

What manufacturing and geographic IP barriers apply?

Omlonti manufacturing requires sterile ophthalmic processing, validated filling, container-closure integrity, preservative efficacy, and tight control of active concentration. The active ingredient’s low dose increases the importance of blend uniformity, adsorption control, and analytical sensitivity.

Potential manufacturing barriers include:

• High-purity omidenepag-isopropyl supply.
• Control of stereochemistry and related impurities.
• Robust sterile filtration or aseptic processing.
• Low-dose content uniformity.
• Compatibility with plastic bottle components.
• Stability after repeated opening.
• Container-closure performance over the labeled shelf life.
• Qualification of specialized preservative-free devices.

Geographic protection may differ among the United States, Japan, Europe, Canada, and other markets. Santen’s Eybelis product in Japan and Omlonti in North America reflect territory-specific commercialization. Patent term, regulatory exclusivity, Orange Book listing practice, and generic approval rules vary by jurisdiction. A U.S. patent position does not establish equivalent protection in Europe, Japan, or emerging markets.

What is the commercial opportunity for Omlonti excipient innovation?

The largest opportunity is a lifecycle-management program rather than a new conventional preserved formulation. Priority concepts are:

1. Preservative-free multidose Omlonti.
2. Unit-dose Omlonti for ocular-surface-sensitive patients.
3. Lower-volume or metered-dose delivery.
4. A combination product with another compatible glaucoma agent.
5. A formulation with improved comfort or reduced post-dose irritation.
6. A device-enabled adherence product with dose tracking or controlled dispensing.

Revenue exposure is concentrated in the chronic-use glaucoma market. Product-level Omlonti revenue is not separately reported in the FDA approval materials. Its value depends on prescription volume, net price, payer coverage, persistence, and the timing of generic or therapeutic substitution. A reformulated product could preserve revenue after base-product patent or exclusivity pressure, but only if the new presentation earns reimbursement and demonstrates a meaningful clinical or adherence advantage.

Key Takeaways

• Omlonti is a once-daily omidenepag isopropyl ophthalmic solution for ocular hypertension and open-angle glaucoma.
• Its commercial formulation uses glycerin, phosphate buffers, polysorbate 80, disodium edetate, BAK, and water.
• BAK supports multidose sterility but creates a clear opportunity for preservative-free lifecycle management.
• The strongest formulation strategy is a preservative-free multidose device or unit-dose presentation.
• Excipient patents are likely less durable than active-ingredient, use, manufacturing, and device claims.
• FDA NCE exclusivity began with the September 2022 approval and generally creates a five-year approval barrier for conventional ANDA products, subject to the statutory framework.
• Generic risk depends on Orange Book-listed patents, formulation design-around opportunities, and the remaining active-ingredient patent term.
• Bausch + Lomb’s North American commercialization rights and Santen’s molecule ownership create a licensing structure relevant to future reformulation deals.
• The main commercial threat is substitution by low-cost prostaglandin generics.
• The main commercial opportunity is differentiated delivery for patients with preservative intolerance, ocular-surface disease, or adherence problems.

FAQs About Omlonti Excipient and Commercial Strategy

Can Omlonti be reformulated without benzalkonium chloride?

Yes. A preservative-free version could use unit-dose packaging or a validated preservative-free multidose device. The reformulation would require new stability, sterility, microbial, packaging, and regulatory data.

Is polysorbate 80 essential to Omlonti?

The FDA label identifies polysorbate 80 as an inactive ingredient, but the public label does not establish that it is irreplaceable. A generic or lifecycle formulation could investigate other solubilizers or surfactants, subject to stability and ocular-tolerability requirements.

Could a preservative-free Omlonti obtain new patent protection?

Yes. A new patent could potentially cover a preservative-free composition, a specific pH or buffer system, a stability profile, a device, or a combination of formulation and packaging features. Patentability would depend on novelty, nonobviousness, claim scope, and prior art.

Is Omlonti at risk from biosimilars?

No. Omlonti is a small-molecule ophthalmic drug, not a biologic. It faces generic-drug and therapeutic-substitution risk rather than biosimilar competition.

Which Omlonti opportunity is most commercially attractive?

A preservative-free multidose presentation has the strongest strategic rationale because it combines chronic-use differentiation, packaging-based IP potential, and improved positioning against preserved glaucoma therapies.

References

1. U.S. Food and Drug Administration. (2022). Omlonti (omidenepag isopropyl ophthalmic solution) prescribing information.
2. Bausch + Lomb. (2022). Bausch + Lomb announces U.S. FDA approval of Omlonti for the reduction of elevated intraocular pressure.
3. European Medicines Agency. (2021). Benzalkonium chloride in medicinal products for ocular use: Scientific conclusions and regulatory recommendations.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certification requirements.
6. Santen Pharmaceutical Co., Ltd. (2020). Santen and Bausch + Lomb collaboration for omidenepag ophthalmic solution in the United States and Canada.